Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quest DiagnosticsMIL:1QDX 54 Buyback Yield % is 0.00 as of Jul. 21, 2026. GuruFocus rates MIL:1QDX with a GF Score™ of 54/100 and a GF Value™ of €163.64 (Fairly Valued). The stock has 8 warning signs investors should review. Among 90 Medical Diagnostics & Research companies, Quest Diagnostics ranks worse than 1111110% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Quest Diagnostics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1QDX vs LH, MTD, GH: Buyback Yield % Comparison
For the Diagnostics & Research subindustry, Quest Diagnostics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Diagnostics Buyback Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Quest Diagnostics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Quest Diagnostics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest Diagnostics (MIL:1QDX) has a Buyback Yield % of 0.00 as of Jul. 21, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Quest Diagnostics and its competitors. Over the past decade, Quest Diagnostics' Buyback Yield % has ranged from 0.90 to 13.50. According to the industry distribution chart, Quest Diagnostics ranks #999999 out of 90 companies in the Medical Diagnostics & Research industry.
Is Quest Diagnostics' Buyback Yield % too high?
Quest Diagnostics' current Buyback Yield % is 0.00. Over the past 10 years, this metric has ranged from a low of 0.90 to a high of 13.50. Based on the distribution chart, Quest Diagnostics ranks #999999 out of 90 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Quest Diagnostics has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Quest Diagnostics' Buyback Yield % compare to LH and MTD?
According to the Medical Diagnostics & Research industry distribution chart, Quest Diagnostics ranks #999999 out of 90 companies for Buyback Yield %. This places Quest Diagnostics in the lower half of its industry. Historically, Quest Diagnostics' own Buyback Yield % has ranged from 0.90 to 13.50 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Diagnostics & Research company?
A good Buyback Yield % depends on the Medical Diagnostics & Research industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Quest Diagnostics and its competitors. Quest Diagnostics's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Quest Diagnostics (MIL:1QDX) is currently considered Fairly Valued. The stock's GF Value™ is €163.64, compared to a current price of €180.35 — trading 10.2% above its estimated fair value. The current Buyback Yield % is 0.00. Quest Diagnostics' overall GF Score™ is 54/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Quest Diagnostics (MIL:1QDX), the current Buyback Yield % is 0.00 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Quest Diagnostics (MIL:1QDX) Overvalued in 2026?
Based on GuruFocus' analysis, Quest Diagnostics stock appears to be overvalued.
The current stock price of €180.35 is trading 10.2% above its estimated GF Value™ of €163.64.
GuruFocus considers Quest Diagnostics to be Fairly Valued.
Key valuation signals for MIL:1QDX:
Buyback Yield %: 0.00
GF Value™: €163.64 vs. price of €180.35 (10.2% above fair value)
No single metric tells the full story. See the MIL:1QDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
54GF Score
Get the complete analysis for MIL:1QDX
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1QDX has been successfully added to your 
